Cynk Technology Corp/ US23258A1088 /
- - | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
-USD | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | - | - |
GlobeNewswire
4/8
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells ...
GlobeNewswire
2/15/2022
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Develo...
GlobeNewswire
1/18/2022
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Develop...
GlobeNewswire
12/27/2021
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Develop...
GlobeNewswire
12/13/2021
Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allo...
GlobeNewswire
11/29/2021
Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer ...
GlobeNewswire
11/15/2021
Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the ...
GlobeNewswire
11/12/2021
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
GlobeNewswire
9/20/2021
Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placent...
GlobeNewswire
9/20/2021
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placent...
GlobeNewswire
7/16/2021
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
GlobeNewswire
7/7/2021
Celularity Founder, Chairman and Chief Executive Officer, Robert J. Hariri, M.D., Ph.D., Dually Awar...
GlobeNewswire
6/29/2021
Celularity Announces Expansion of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cel...
GlobeNewswire
5/20/2021
Celularity Appoints Bradley Glover, Ph.D. as Executive Vice President and Chief Technology Officer
GlobeNewswire
4/13/2021
Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatmen...
GlobeNewswire
4/9/2021
Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) A...
GlobeNewswire
3/18/2021
Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 ...
GlobeNewswire
5/21/2020
Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic ...
GlobeNewswire
4/2/2020
SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGIN...
GlobeNewswire
1/29/2020
Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Developmen...
GlobeNewswire
3/22/2017
Lumenis Unveils its new Moses(TM) Technology at European Association of Urology Annual Congress